Cargando…
Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based on a small number of peptide ligands and binding as...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566978/ https://www.ncbi.nlm.nih.gov/pubmed/28871256 http://dx.doi.org/10.3389/fimmu.2017.00984 |
_version_ | 1783258633164816384 |
---|---|
author | Scholz, Erika Margaret Marcilla, Miguel Daura, Xavier Arribas-Layton, David James, Eddie A. Alvarez, Iñaki |
author_facet | Scholz, Erika Margaret Marcilla, Miguel Daura, Xavier Arribas-Layton, David James, Eddie A. Alvarez, Iñaki |
author_sort | Scholz, Erika Margaret |
collection | PubMed |
description | Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based on a small number of peptide ligands and binding assays. DR2a could display a set of peptides complementary to that presented by DR2b or, alternatively, a similar peptide repertoire but recognized in a different manner by T cells. It is known that DR2a and DR2b share some peptide ligands, although the degree of similarity of their associated peptidomes remains unclear. In addition, the contribution of each molecule to the global peptide repertoire presented by the HLA-DR15 haplotype has not been evaluated. We used mass spectrometry to analyze the peptide pools bound to DR2a and DR2b, identifying 169 and 555 unique peptide ligands of DR2a and DR2b, respectively. The analysis of these sets of peptides allowed the refinement of the corresponding binding motifs revealing novel anchor residues that had been overlooked in previous analyses. Moreover, the number of shared ligands between both molecules was low, indicating that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, our analysis suggests that, quantitatively, both molecules contribute to the peptide repertoire presented by cells expressing the HLA-DR15 haplotype. |
format | Online Article Text |
id | pubmed-5566978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55669782017-09-04 Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires Scholz, Erika Margaret Marcilla, Miguel Daura, Xavier Arribas-Layton, David James, Eddie A. Alvarez, Iñaki Front Immunol Immunology Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based on a small number of peptide ligands and binding assays. DR2a could display a set of peptides complementary to that presented by DR2b or, alternatively, a similar peptide repertoire but recognized in a different manner by T cells. It is known that DR2a and DR2b share some peptide ligands, although the degree of similarity of their associated peptidomes remains unclear. In addition, the contribution of each molecule to the global peptide repertoire presented by the HLA-DR15 haplotype has not been evaluated. We used mass spectrometry to analyze the peptide pools bound to DR2a and DR2b, identifying 169 and 555 unique peptide ligands of DR2a and DR2b, respectively. The analysis of these sets of peptides allowed the refinement of the corresponding binding motifs revealing novel anchor residues that had been overlooked in previous analyses. Moreover, the number of shared ligands between both molecules was low, indicating that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, our analysis suggests that, quantitatively, both molecules contribute to the peptide repertoire presented by cells expressing the HLA-DR15 haplotype. Frontiers Media S.A. 2017-08-21 /pmc/articles/PMC5566978/ /pubmed/28871256 http://dx.doi.org/10.3389/fimmu.2017.00984 Text en Copyright © 2017 Scholz, Marcilla, Daura, Arribas-Layton, James and Alvarez. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Scholz, Erika Margaret Marcilla, Miguel Daura, Xavier Arribas-Layton, David James, Eddie A. Alvarez, Iñaki Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
title | Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
title_full | Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
title_fullStr | Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
title_full_unstemmed | Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
title_short | Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
title_sort | human leukocyte antigen (hla)-drb1*15:01 and hla-drb5*01:01 present complementary peptide repertoires |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566978/ https://www.ncbi.nlm.nih.gov/pubmed/28871256 http://dx.doi.org/10.3389/fimmu.2017.00984 |
work_keys_str_mv | AT scholzerikamargaret humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires AT marcillamiguel humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires AT dauraxavier humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires AT arribaslaytondavid humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires AT jameseddiea humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires AT alvarezinaki humanleukocyteantigenhladrb11501andhladrb50101presentcomplementarypeptiderepertoires |